WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Medical, Industry Outlook
PRNewswire | June 19, 2023
"We care for your samples, you care for science" – Singleron holds true to their slogan as reliable partner to scientists and clinicians. Developing single cell multi-omics products that can be used in research and clinical settings, the launch of two new instruments extends their current portfolio that delivers one-stop-shop solutions for the single cell sequencing workflow.
Scientists and clinical researchers appreciate the prospect of portable instruments that...
Zivo | June 28, 2022
ZIVO Bioscience, Inc. is a U.S.-based R&D company dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains, announced joining the Russell Microcap® Index (^RUMIC) as a result of the Russell indexes annual reconstitution in 2022.
Russell Microcap® Index membership that remains in place for a course of 12 months, means automatic inclusion in the appropriate value style and gr...
Deargen | April 12, 2021
Deargen, a drug research and development biotech company based on artificial intelligence (AI), announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference, and Learning (ACM CHIL) 2021. CMG technology can modify many properties of molecules at the same time.
The Association for Computing Machinery (ACM), based in New York, is one of the world's most prominent academic organizations. The ACM ...
Enveric Biosciences, Inc | July 14, 2022
Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022.
“The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy Psy...
Industrial Impact, Medical
MedTech, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE